Peptide therapy excitement on TikTok: hype vs. actual evidence

What did @realalejandroreyes actually say?

The creator is running testosterone cypionate at 300mg per week alongside what sounds like semaglutide (referred to as "the R-word"), IGF-1 LR3 or similar, GHK-Cu, NAD+, and glutathione. He switched off "test of Premo" (likely testosterone propionate or a premixed blend) due to hair loss. His main pitch: semaglutide reduces appetite, IGF-1 directs nutrients toward muscle instead of fat, GHK-Cu improves skin and hair, NAD+ clears toxins and boosts energy. He frames this as a body recomposition stack, not a therapeutic protocol. That distinction matters.

He also says IGF-1 helps "put food portion in meaning" so nutrients go "towards more of your muscle bellies rather than fat storage." That is a specific partitioning claim worth scrutinizing. So is the phrase "flush out toxicity" applied to NAD+.

Does the science back this up?

Some of it, partially. Semaglutide's appetite suppression is the most evidence-backed claim here. IGF-1's muscle partitioning effects are real but wildly overstated in the fitness community. GHK-Cu skin data is promising but mostly preclinical. NAD+ "flushing toxins" is not a real mechanism.

Semaglutide (a GLP-1 receptor agonist) does reduce appetite and body weight. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 14.9% mean body weight reduction over 68 weeks. That is legitimate. The "targets your GLP-1 receptors" claim is roughly accurate, though he says "gluten receptors," which is clearly a verbal slip.

IGF-1's nutrient partitioning role is supported in some research, but the evidence comes mostly from GH-deficient populations or pharmacological doses. Barton (2006, Journal of Physiology) reviewed IGF-1's anabolic signaling, but extrapolating that to "quicker size and muscle" in a healthy person using exogenous IGF-1 peptides is a significant leap. The safety profile of exogenous IGF-1 in non-clinical settings is also not well established.

GHK-Cu has shown collagen-stimulating and wound-healing effects in cell studies (Pickart et al., 2015, Journal of Aging Research), but human clinical trials on topical or injectable GHK-Cu for skin rejuvenation are limited. The hair claim is even thinner on human data.

NAD+ supplementation has emerging support for cellular energy metabolism (Yoshino et al., 2021, Science), but "flushes toxicity" is not a documented mechanism. That phrasing borrows from detox marketing, not biochemistry.

What did they get wrong (or right)?

He got semaglutide's appetite mechanism roughly right and the GHK-Cu skin plausibility is fair. But several claims cross the line into overstatement or are simply wrong.

Saying IGF-1 "helps you put on size and muscle quicker" as a straightforward outcome ignores that exogenous IGF-1 peptides are not approved, their bioavailability varies enormously depending on form and source, and the dose-response data in healthy adults is weak. Presenting it as a reliable muscle-building tool is misleading.

The NAD+ "flush out toxicity" claim is inaccurate. NAD+ is a coenzyme involved in redox reactions and cellular energy, not a detoxification agent in any established sense. This is a common mischaracterization that conflates NAD+'s role in sirtuin activation and mitochondrial function with the very different concept of hepatic or renal detox pathways.

Running testosterone at 300mg per week alongside multiple unregulated peptides and a GLP-1 agonist is a complex, unstudied combination. No published trial has evaluated this stack. Presenting it as an optimized protocol without mentioning that is a significant omission.

What should you actually know?

If you are considering any of these compounds, the regulatory and safety picture is complicated and the creator does not address it at all.

Semaglutide is FDA-approved under brand names for diabetes and obesity management, but compounded semaglutide exists in a legal gray zone following recent FDA enforcement updates. IGF-1 peptides sold through peptide vendors are not FDA-approved for human use. GHK-Cu is available as a research peptide and in some cosmetic formulations, but injectable versions are not regulated as drugs. NAD+ precursors like NMN or NR are available as supplements with some clinical backing, but IV or injectable NAD+ carries its own risk profile.

Stacking a GLP-1 agonist with anabolic compounds also raises questions about cardiovascular load, insulin sensitivity shifts, and the interaction between accelerated muscle protein synthesis signaling from IGF-1 and the caloric deficit driven by semaglutide. That combination has not been studied. Weight loss driven by semaglutide in the presence of supraphysiological testosterone may change the risk-benefit calculus in ways that are not yet understood.

Anyone watching this should understand this is one person's self-reported cycle, not a protocol with medical oversight. The enthusiasm is real. The evidence base for this specific combination is not.